{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:36:41Z","timestamp":1792805801474,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T00:00:00Z","timestamp":1336953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K99CA139006-01A1"],"award-info":[{"award-number":["1K99CA139006-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nellie B. Connally Breast Cancer Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The mitogen-activated protein kinase (MAPK) signaling pathway is known to be activated in triple-negative breast cancer (TNBC). Extracellular signal\u2013related kinase (ERK), a member of the MAPK pathway, promotes cell proliferation, angiogenesis, cell differentiation, and cell survival. To assess the prognostic impact of ERK in TNBC patients, relative quantities of ERK (ERK-2 and pMAPK) and direct targets of the ERK pathway (MAPK\/ERK kinase 1, phospho-enriched protein in astrocytes [PEA]-15, phosphorylated (p)PEA-15, tuberous sclerosis protein 2, p70S6 kinase, and p27) were measured using reverse-phase protein arrays in tumor tissue from patients with TNBC (n = 97) and non-TNBC (n = 223). Protein levels in patients with TNBC were correlated with clinical and tumor characteristics and outcome. The median age of patients with TNBC was 55 years (range, 27\u201386 years). Disease stage was I in 21%, II in 60%, and III in 20% of the patients. In a multivariate analysis, among patients with TNBC, those with ERK-2\u2013overexpressing tumors had a lower overall survival rate than those with low ERK-2\u2013expressing tumors (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.19\u20136.41). However, high pMAPK levels were associated with a significantly higher relapse-free survival rate (HR, 0.66; 95% CI, 0.46\u20130.95). In conclusion, ERK-2 and pMAPK are valuable prognostic markers in TNBC. Further studies are justified to elucidate ERK's role in TNBC tumorigenicity and metastasis.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0377","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T05:10:41Z","timestamp":1337058641000},"page":"766-774","source":"Crossref","is-referenced-by-count":125,"title":["High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients"],"prefix":"10.1093","volume":"17","author":[{"given":"Chandra","family":"Bartholomeusz","sequence":"first","affiliation":[{"name":"a Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"b Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gonzalez-Angulo","sequence":"additional","affiliation":[{"name":"b Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"c Departments of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"d Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"a Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"b Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lluch","sequence":"additional","affiliation":[{"name":"e Hematology-Oncology and Pathology, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Ferrer-Lozano","sequence":"additional","affiliation":[{"name":"e Hematology-Oncology and Pathology, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortob\u00e1gyi","sequence":"additional","affiliation":[{"name":"a Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"b Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,14]]},"reference":[{"key":"2021122308235846200_B1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543780903222268","article-title":"Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: Empiricism or evidence-based?","volume":"18","author":"Petrelli","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122308235846200_B2","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","article-title":"Basal-like breast cancer: A critical review","volume":"26","author":"Rakha","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308235846200_B3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"5","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122308235846200_B4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdm522","article-title":"MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer","volume":"19","author":"Eralp","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308235846200_B5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1349-7006.2007.00622.x","article-title":"Increased phosphorylation of Akt in triple-negative breast cancers","volume":"98","author":"Umemura","year":"2007","journal-title":"Cancer Sci"},{"key":"2021122308235846200_B6","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1074\/jbc.274.7.4347","article-title":"Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration","volume":"274","author":"McCawley","year":"1999","journal-title":"J Biol Chem"},{"key":"2021122308235846200_B7","first-page":"1747","article-title":"Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression","volume":"8","author":"Adeyinka","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122308235846200_B8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.onc.1209014","article-title":"Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15","volume":"25","author":"Bartholomeusz","year":"2006","journal-title":"Oncogene"},{"key":"2021122308235846200_B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1534-5807(01)00035-1","article-title":"PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase","volume":"1","author":"Formstecher","year":"2001","journal-title":"Dev Cell"},{"key":"2021122308235846200_B10","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1093\/emboj\/cdf641","article-title":"Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain","volume":"21","author":"Hill","year":"2002","journal-title":"EMBO J"},{"key":"2021122308235846200_B11","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.1074\/jbc.M310031200","article-title":"The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions","volume":"279","author":"Whitehurst","year":"2004","journal-title":"J Biol Chem"},{"key":"2021122308235846200_B12","doi-asserted-by":"crossref","first-page":"33897","DOI":"10.1074\/jbc.273.51.33897","article-title":"The death effector domain of PEA-15 is involved in its regulation of integrin activation","volume":"273","author":"Ramos","year":"1998","journal-title":"J Biol Chem"},{"key":"2021122308235846200_B13","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1091\/mbc.11.9.2863","article-title":"Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion- independent mechanism","volume":"11","author":"Ramos","year":"2000","journal-title":"Mol Biol Cell"},{"key":"2021122308235846200_B14","doi-asserted-by":"crossref","first-page":"52587","DOI":"10.1074\/jbc.M309322200","article-title":"PEA-15 binding to ERK1\/2 MAPKs is required for its modulation of integrin activation","volume":"278","author":"Chou","year":"2003","journal-title":"J Biol Chem"},{"key":"2021122308235846200_B15","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/MCB.23.13.4511-4521.2003","article-title":"Protein kinase B\/Akt binds and phosphorylates PED\/PEA-15, stabilizing its antiapoptotic action","volume":"23","author":"Trencia","year":"2003","journal-title":"Mol Cell Biol"},{"key":"2021122308235846200_B16","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1091\/mbc.e04-11-1007","article-title":"Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal-regulated kinase-dependent transcription and cell proliferation","volume":"16","author":"Krueger","year":"2005","journal-title":"Mol Biol Cell"},{"key":"2021122308235846200_B17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1158\/0008-5472.CAN-06-1378","article-title":"PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1\/2","volume":"67","author":"Glading","year":"2007","journal-title":"Cancer Res"},{"key":"2021122308235846200_B18","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/1078-0432.CCR-09-1456","article-title":"PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase","volume":"16","author":"Bartholomeusz","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308235846200_B19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"key":"2021122308235846200_B20","doi-asserted-by":"crossref","first-page":"C652","DOI":"10.1152\/ajpcell.1999.277.4.C652","article-title":"MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells","volume":"277","author":"Rivard","year":"1999","journal-title":"Am J Physiol"},{"key":"2021122308235846200_B21","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1158\/1078-0432.CCR-08-1763","article-title":"Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer","volume":"15","author":"Gonzalez-Angulo","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308235846200_B22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S","article-title":"Phosphorylation of ERK1\/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer","volume":"95","author":"Gee","year":"2001","journal-title":"Int J Cancer"},{"key":"2021122308235846200_B23","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1210\/endo.142.7.8259","article-title":"Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)","volume":"142","author":"McClelland","year":"2001","journal-title":"Endocrinology"},{"key":"2021122308235846200_B24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R","article-title":"Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients","volume":"89","author":"Mueller","year":"2000","journal-title":"Int J Cancer"},{"key":"2021122308235846200_B25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308235846200_B26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: Intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"2021122308235846200_B27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1124\/mol.60.2.290","article-title":"Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines","volume":"60","author":"McDaid","year":"2001","journal-title":"Mol Pharmacol"},{"key":"2021122308235846200_B28","doi-asserted-by":"crossref","first-page":"38953","DOI":"10.1074\/jbc.C000684200","article-title":"MEK inhibition enhances paclitaxel-induced tumor apoptosis","volume":"275","author":"MacKeigan","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122308235846200_B29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/sj.bjc.6604915","article-title":"Relation between outcomes and localisation of p-mTOR expression in gastric cancer","volume":"100","author":"Murayama","year":"2009","journal-title":"Br J Cancer"},{"key":"2021122308235846200_B30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1091\/mbc.e09-08-0659","article-title":"Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) reprograms growth factor signaling by inhibiting threonine phos-phorylation of fibroblast receptor substrate 2\u03b1","volume":"21","author":"Haling","year":"2010","journal-title":"Mol Biol Cell"},{"key":"2021122308235846200_B31","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.1158\/0008-5472.CAN-08-2592","article-title":"PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival","volume":"15;68","author":"Bartholomeusz","year":"2008","journal-title":"Cancer Res"},{"key":"2021122308235846200_B32","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1016\/S0021-9258(18)53407-4","article-title":"Characterization of PEA-15, a major substrate for protein kinase C in astrocytes","volume":"268","author":"Araujo","year":"1993","journal-title":"J Biol Chem"},{"key":"2021122308235846200_B33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/dbio.1999.9510","article-title":"The phosphoprotein protein PEA-15 inhibits Fas- but increases TNF-R1-mediated caspase-8 activity and apoptosis","volume":"216","author":"Estell\u00e9s","year":"1999","journal-title":"Dev Biol"},{"key":"2021122308235846200_B34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-005-4794-6","article-title":"Inhibition of either phosphatidylinositol 3-kinase\/Akt or the mitogen\/extracellular-regulated kinase, MEK\/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK\/ERK signaling is critical for cell survival","volume":"93","author":"Ripple","year":"2005","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/6\/766\/41860222\/oncolo_17_6_766.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/6\/766\/41860222\/oncolo_17_6_766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:12:39Z","timestamp":1640297559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/6\/766\/6400987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,14]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,5,14]]},"published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0377","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,1]]},"published":{"date-parts":[[2012,5,14]]}}}